- Motley Fool•1 hour ago
One has tremendous upside potential, the other is heading for stable growth. To choose the better stock, we'll see how well they stack up.
- Motley Fool•7 days ago
Pfizer, Johnson & Johnson, and Roche are all poised to have a stellar 2017.
- Zacks•7 days ago
Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.
RHHBY : Summary for ROCHE HLDGS AG SPN ADR EACH REP - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||29.35 - 29.46|
|52 Week Range||25.25 - 33.77|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||22.66|
|Dividend & Yield||1.02 (3.44%)|
|1y Target Est||N/A|